Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9018905 | 0.87 | TSHR (0.54) | TSHRCA1CA2CA9CYP1A2 | |
| SCHEMBL23003 | 0.87 | TSHR (0.79) | TSHRCA1CA2CA9KMT2A | |
| SCHEMBL28370887 | 0.85 | TSHR (0.76) | TSHRCA1CA2CA9KMT2A | |
| Ammonia Solution, Strong SCHEMBL27527756 | 0.85 | TSHR (0.76) | TSHRCA1CA2CA9KMT2A | |
| SCHEMBL5515624 | 0.84 | FOLH1 (0.56) | TSHRCYP1A2CYP2C19KMT2AFOLH1 | |
| SCHEMBL1500536 | 0.84 | TSHR (0.51) | TSHRCA1CA2CA9CYP1A2 | |
| SCHEMBL7759867 | 0.84 | TSHR (0.74) | TSHRCA1CA2CA9FOLH1 | |
| SCHEMBL29580520 | 0.84 | TSHR (0.74) | TSHRCA1CA2CA9FOLH1 | |
| SCHEMBL69041 | 0.84 | TSHR (1.00) | TSHRCA1CA2CA9CYP1A2 | |
| SCHEMBL2292722 | 0.84 | TSHR (0.74) | TSHRCA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126819-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-1789375-B1 | PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-09 | — | — | EP | disclosed |
| EP-1789375-B1 | PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-09 | — | — | EP | disclosed |
| CN-100591652-C | Method for producing 2-(4-fluoro-benzyl)-phenyl-acetic acid | JANSSEN PHARMACEUTICA NV | 2010-02-24 | — | — | CN | disclosed |
| US-7470809-B2 | Process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470809-B2 | Process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470809-B2 | Process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-20070213556-A1 | NOVEL PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213556-A1 | NOVEL PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213556-A1 | NOVEL PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20050033067-A1 | Preparation of cis-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives | HUA MAO (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050014820-A1 | Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2005-01-20 | — | — | US | disclosed |
| EP-1463722-A2 | PREPARATION OF CIS-FUSED 3,3a,8,12b-TETRAHYDRO-2-H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1456193-A1 | PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2 i H /i -DIBENZO 3,4:6,7]CYCLOHEPTA 1,2-b]FURAN DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-15 | — | — | EP | disclosed |
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| WO-2003048147-A2 | PREPARATION OF CIS-FUSED 3,3a,8,12b-TETRAHYDRO-2H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048146-A1 | PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-12 | — | — | WO | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033067-A1 | Preparation of cis-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives | CYP4F3, DHFR, CYP11B1 | TSHR 2710/4885CA1 1743/4885CA2 2960/4885 |
| US-20070213556-A1 | NOVEL PROCESS FOR THE PRODUCTION OF [2-(4-FLUORO-BENZYL)-PHENYL]-ACETIC ACID | ADH1A, ADH1C, CA4 | TSHR 4002/4885CA1 12/4885CA2 6/4885 |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | TSHR 509/4885CA1 2322/4885CA2 1696/4885 |
| US-20050014820-A1 | Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives | CYP4F3, DHFR, CYP4F8 | TSHR 1801/4885CA1 2075/4885CA2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.